Obeticholic acid (OCA), which is a well-known bile acid and accepted drug for NASH, is known to significantly improve liver fibrosis via FXR (Younossi et al., 2022). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.